Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Whitehawk Therapeutics (WHWK) over the last 4 years, with Q3 2025 value amounting to $124.7 million.

  • Whitehawk Therapeutics' Short-term Investments rose 28858.55% to $124.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.7 million, marking a year-over-year increase of 28858.55%. This contributed to the annual value of $18.6 million for FY2024, which is 5959.92% down from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Short-term Investments is $124.7 million, which was up 28858.55% from $32.3 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Short-term Investments registered a high of $133.5 million during Q4 2022, and its lowest value of $3.5 million during Q1 2025.
  • For the 4-year period, Whitehawk Therapeutics' Short-term Investments averaged around $57.3 million, with its median value being $46.0 million (2023).
  • Over the last 5 years, Whitehawk Therapeutics' Short-term Investments had its largest YoY gain of 28858.55% in 2025, and its largest YoY loss of 8987.27% in 2025.
  • Quarter analysis of 4 years shows Whitehawk Therapeutics' Short-term Investments stood at $133.5 million in 2022, then crashed by 65.59% to $46.0 million in 2023, then tumbled by 59.6% to $18.6 million in 2024, then surged by 571.44% to $124.7 million in 2025.
  • Its Short-term Investments stands at $124.7 million for Q3 2025, versus $32.3 million for Q2 2025 and $3.5 million for Q1 2025.